A Study of TL-925 for the Treatment of Allergic Conjunctivitis

NCT06153342 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Allergic Conjunctivitis

Interventions

DRUG: TL-925
DRUG: Placebo

Sponsor

Telios Pharma, Inc.